专题：Prostate Cancer Treatment and Research

This cluster of papers represents a comprehensive exploration of advancements in prostate cancer research, covering topics such as androgen receptor signaling, genomic profiling, hormone therapy, immunotherapy, genetic mutations, clinical trials, biomarkers, and molecular biology. The papers discuss the molecular determinants of resistance to antiandrogen therapy, the impact of translocations and gene fusions on cancer causation, and the development of second-generation antiandrogens for the treatment of advanced prostate cancer.
最新文献
The Number of Cancer-Involved Regions in Patients With Prostate Cancer Diagnosed by Magnetic Resonance Imaging/Ultrasound-Guided Fusion Prostate Biopsy Is a New Tumor Metric Associated With the Increased Risk of Adverse Pathology at Radical Prostatectomy

article Full Text OpenAlex

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

article Full Text OpenAlex

Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation

article Full Text OpenAlex

Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies

article Full Text OpenAlex

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex

Reprogramming prostate cancer through the microbiome

review Full Text OpenAlex

The Clinical Relevance of Tumor Biomarkers in Prostate Cancer—A Review

review Full Text OpenAlex

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

article Full Text OpenAlex

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer

article Full Text OpenAlex

LBA92 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial

article Full Text OpenAlex

近5年高被引文献
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent

review Full Text OpenAlex 875 FWCI375.7797

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

article Full Text OpenAlex 839 FWCI120.2235

Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches

review Full Text OpenAlex 793 FWCI113.232

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

article Full Text OpenAlex 727 FWCI103.9607

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

article Full Text OpenAlex 678 FWCI178.4023

Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019

article Full Text OpenAlex 613 FWCI91.3456

The Lancet Commission on prostate cancer: planning for the surge in cases

review Full Text OpenAlex 537 FWCI231.3295

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 522 FWCI136.3877

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

article Full Text OpenAlex 459 FWCI107.3694

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management

article Full Text OpenAlex 401 FWCI56.865